Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Amgen(US:AMGN) Benzinga·2026-01-30 18:09Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where are AMGN shares going?Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.The business decision is the result of a strategic portfolio prioritization by Amgen.In June 2021, Amgen and Kyowa Kirin agreed to jointly develop and commercialize KH ...